Haemonetics projects FY 2027 revenue growth of 4% to 7% as Persona PLUS rollout and IVT rebound efforts continue
Source: SeekingAlpha
2026-05-08 02:42:50 ET
More on Haemonetics
- Haemonetics Corporation (HAE) Q4 2026 Earnings Call Transcript
- Haemonetics Q4 2026 Earnings Preview
- Seeking Alpha’s Quant Rating on Haemonetics
- Historical earnings data for Haemonetics
- Financial information for Haemonetics
Read the full article on Seeking Alpha
For further details see:
Haemonetics projects FY 2027 revenue growth of 4% to 7% as Persona PLUS rollout and IVT rebound efforts continue
Haemonetics Corporation
NASDAQ: HAE
HAE Trading
3.69% G/L:
$71.435 Last:
243,692 Volume:
$70.10 Open:
HAE Latest News
June 02, 2026 04:05:00 pm
Haemonetics to Present at Goldman Sachs 47th Annual Global Healthcare Conference
HAE Stock Data
$2,748,315,639
45,616,277
0.08%
124
N/A
Medical Equipment & Supplies
Healthcare
US
Boston
